Last reviewed · How we verify
ND1.1
At a glance
| Generic name | ND1.1 |
|---|---|
| Also known as | Ad-HA-dsRNA |
| Sponsor | Vaxart |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity of ND1.1 by Delivery Directly to the Ileum (PHASE1)
- Safety Study of an Oral Vaccine to Prevent Avian Influenza (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ND1.1 CI brief — competitive landscape report
- ND1.1 updates RSS · CI watch RSS
- Vaxart portfolio CI